Grew Total Revenue to $75.6 million , an Increase of 25% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022 .
- New findings reinforce potential of company’s multi-omics capabilities and tools in immuno-oncology to address biopharma partners’ unique oncology drug development needs - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 27, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Credit Suisse 31 st Annual Healthcare Conference on
Findings shared in an oral presentation at ASTRO Annual Meeting 2022 suggest predictive biomarker could help guide treatment in men experiencing disease progression after surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2022-- Veracyte, Inc .
Findings Derived from Company’s Extensive Thyroid Nodule Database and Whole-Transcriptome Capabilities SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 24, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 18, 2022-- Veracyte, Inc . (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2022 after the close of market on Wednesday, November 2, 2022 . Company management will host a conference call and webcast to
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 22, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite , Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte’s plan to expand test availability in the U.S.
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
